uniQure N.V.
NASDAQuniQure heads into its May 5 Q1 print carrying a double dose of catalysts — a fresh UK regulatory milestone announced this morning and a stock that fell 7% on Wednesday, extending losses into what has been a pivotal week for the gene therapy company. The headline news is the MHRA development. uniQure confirmed this morning it has completed a successful pre-submission meeting with…
Snapshot as of 8 May 2026
uniQure heads into its May 5 Q1 print carrying a double dose of catalysts — a fresh UK regulatory milestone announced this morning and a stock that fell 7% on Wednesday, extending losses into what has been a pivotal…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for QURE — free to start on ORTEX.
Sign up for free →Open QURE on ORTEX